DD201897A5 - Verfahren zur herstellung von 3,4-bis-substituierten 1,2,5-oxdiazol-2-oxiden - Google Patents

Verfahren zur herstellung von 3,4-bis-substituierten 1,2,5-oxdiazol-2-oxiden Download PDF

Info

Publication number
DD201897A5
DD201897A5 DD81233917A DD23391781A DD201897A5 DD 201897 A5 DD201897 A5 DD 201897A5 DD 81233917 A DD81233917 A DD 81233917A DD 23391781 A DD23391781 A DD 23391781A DD 201897 A5 DD201897 A5 DD 201897A5
Authority
DD
German Democratic Republic
Prior art keywords
formula
deep
items
atoms
bis
Prior art date
Application number
DD81233917A
Other languages
German (de)
English (en)
Inventor
Schoenafinger
Beyerle
Mogilev
Bohn
Just
Martorana
Nitz
Original Assignee
Cassella Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassella Ag filed Critical Cassella Ag
Publication of DD201897A5 publication Critical patent/DD201897A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Materials For Photolithography (AREA)
DD81233917A 1980-12-18 1981-10-06 Verfahren zur herstellung von 3,4-bis-substituierten 1,2,5-oxdiazol-2-oxiden DD201897A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803047730 DE3047730A1 (de) 1980-12-18 1980-12-18 3,4-bis-substituierte 1,2,5-oxdiazol-2-oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen

Publications (1)

Publication Number Publication Date
DD201897A5 true DD201897A5 (de) 1983-08-17

Family

ID=6119497

Family Applications (1)

Application Number Title Priority Date Filing Date
DD81233917A DD201897A5 (de) 1980-12-18 1981-10-06 Verfahren zur herstellung von 3,4-bis-substituierten 1,2,5-oxdiazol-2-oxiden

Country Status (28)

Country Link
US (1) US4356178A (pl)
EP (1) EP0054872B1 (pl)
JP (1) JPS57123173A (pl)
KR (1) KR880000543B1 (pl)
AR (1) AR227697A1 (pl)
AT (1) ATE10094T1 (pl)
AU (1) AU542529B2 (pl)
CA (1) CA1157019A (pl)
CS (1) CS219863B2 (pl)
DD (1) DD201897A5 (pl)
DE (2) DE3047730A1 (pl)
DK (1) DK150597C (pl)
ES (1) ES508086A0 (pl)
FI (1) FI813666L (pl)
GR (1) GR81375B (pl)
HK (1) HK51385A (pl)
HU (1) HU183751B (pl)
IE (1) IE52034B1 (pl)
IL (1) IL64563A (pl)
NO (1) NO814045L (pl)
NZ (1) NZ199272A (pl)
PH (1) PH18051A (pl)
PL (1) PL128564B1 (pl)
PT (1) PT74129B (pl)
RO (1) RO84099B (pl)
SG (1) SG21285G (pl)
SU (1) SU1093246A3 (pl)
ZA (1) ZA818726B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507485A (en) * 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
DE4217794A1 (de) * 1992-05-29 1993-12-02 Cassella Ag Phenylfuroxane
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4218979A1 (de) * 1992-06-10 1993-12-16 Cassella Ag Pyrimidofuroxane
DE4220264A1 (de) * 1992-06-20 1993-12-23 Cassella Ag Phenyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
DE4307105A1 (de) * 1993-03-06 1994-09-08 Cassella Ag Hydroxymethylfurazancarbonsäurederivate
US5460669A (en) * 1993-06-28 1995-10-24 Thiokol Corporation 3-nitramino-4-nitrofurazan and salts thereof
DE4401150A1 (de) * 1994-01-17 1995-07-20 Cassella Ag Furazancarbonsäurederivate
JP2008543863A (ja) 2005-06-15 2008-12-04 ハイドラ バイオサイエンシズ インコーポレイテッド 精子の運動亢進のモジュレーター及びその利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089867A (en) * 1976-11-11 1978-05-16 Texaco Inc. Preparation of diacylfurazan oxides

Also Published As

Publication number Publication date
IE812976L (en) 1982-06-18
DE3047730A1 (de) 1982-07-15
NZ199272A (en) 1984-03-16
CS219863B2 (en) 1983-03-25
RO84099B (ro) 1984-06-30
PL234257A1 (pl) 1982-08-02
PH18051A (en) 1985-03-13
AR227697A1 (es) 1982-11-30
JPH0223551B2 (pl) 1990-05-24
HU183751B (en) 1984-05-28
DK533881A (da) 1982-06-19
FI813666L (fi) 1982-06-19
NO814045L (no) 1982-06-21
ATE10094T1 (de) 1984-11-15
EP0054872A1 (de) 1982-06-30
ES8300101A1 (es) 1982-10-01
CA1157019A (en) 1983-11-15
SU1093246A3 (ru) 1984-05-15
DK150597B (da) 1987-04-06
US4356178A (en) 1982-10-26
PL128564B1 (en) 1984-02-29
KR880000543B1 (ko) 1988-04-13
AU542529B2 (en) 1985-02-21
PT74129B (de) 1983-05-16
IL64563A0 (en) 1982-03-31
DK150597C (da) 1987-10-26
GR81375B (pl) 1984-12-11
KR830007596A (ko) 1983-11-04
HK51385A (en) 1985-07-12
IL64563A (en) 1985-02-28
ES508086A0 (es) 1982-10-01
AU7855881A (en) 1982-06-24
RO84099A (ro) 1984-05-12
ZA818726B (en) 1982-11-24
JPS57123173A (en) 1982-07-31
EP0054872B1 (de) 1984-10-31
PT74129A (de) 1982-01-01
DE3167001D1 (en) 1984-12-06
IE52034B1 (en) 1987-05-27
SG21285G (en) 1985-09-13

Similar Documents

Publication Publication Date Title
DE1957706C3 (de) Kernsubstituierte 3-Phenoxy-l-phenoxyalkylamino-propan-2-ole und Arzneimittel auf deren Basis
EP0059356B1 (de) Substituierte 3-Amino-sydnonimine, Verfahren zu ihrer Herstellung und ihre Verwendung
DD201897A5 (de) Verfahren zur herstellung von 3,4-bis-substituierten 1,2,5-oxdiazol-2-oxiden
CH640227A5 (de) Aminoalkoxyphenyl-derivate.
CH622490A5 (en) Process for the preparation of novel hydroxypropylamines
DE3014813A1 (de) 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)benzoesaeure-derivate
EP0054873B1 (de) 3,4-Disubstituierte 1,2,5-Oxadiazol-2-oxide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
DE3800830A1 (de) Substituierte 3-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung
DE2817370A1 (de) Phenyltetrazolyloxy-propanolamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DD209195A5 (de) Verfahren zur herstellung von 1,2,5-oxadiazol-3,4-dicarbonsaeurederivaten
DE2923817C2 (de) (3-Alkylamino-2-hydroxyproposy)-furan-2-carbonsäureanilide und deren physiologisch verträgliche Säureadditionssalze und Verfahren zu deren Herstellung sowie Arzneimittel mit einem Gehalt dieser Verbindungen
DE2137538C3 (de) oxyamin und seine Salze sowie ein Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel
DE2023829C3 (de) Kernsubstituierte 3-Phenoxy-lphenoxyalkyl-amino-propan-2-oIe, Verfahren zu ihrer Herstellung sowie Arzneimittel
DE2062055A1 (de) Propanolamin Derivate
DE1806995C3 (de) Bisimidazolyl-bisphenylmethane und deren Salze
DE2403809C2 (de) 1-Aryloxy-2-hydroxy-3-alkinylaminopropane und Verfahren zu ihrer Herstellung und pharmazeutische Präparate
DE2943406A1 (de) Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols
CH645372A5 (de) 5-(2-((2,3-dihydro-1,4-benzodioxan-2-ylmethyl)amino)-1-hydroxyethyl)-2-hydroxybenzoesaeure-derivate sowie verfahren zu deren herstellung.
DE1545786A1 (de) Verfahren zur Herstellung von Carbonsaeure-N-methylpiperaziden
DE2822473A1 (de) Alkanolaminderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
CH645373A5 (de) 2-hydroxy-5-(1-hydroxy-2-(4-(2-oxo-1-benzimidazolinyl)-piperidino)ethyl)benzoesaeure-derivate sowie verfahren zu deren herstellung.
DE1618160C3 (de) l-(2-Äthinylphenoxy)-2-hydroxy-3alkylaminopropane, ihre physiologisch verträglichen Säureadditionssalze, Verfahren zu ihrer Herstellung, sowie diese Verbindungen enthaltende Arzneimittel
AT298454B (de) Verfahren zur Herstellung von neuen 1-(4'-Acylaminophenoxy)-2-hydroxy-3-aminopropanen und von deren Säureadditionssalzen
AT344186B (de) Verfahren zur herstellung von neuen chinazolinverbindungen und deren saeureadditionssalzen und optisch aktiven formen
AT298458B (de) Verfahren zur Herstellung von neuen 1-(4'-Acylaminophenoxy)-2-hydroxy-3-aminopropanen und von deren Säureadditionssalzen